Lemzoparlimab (TJ011133; TJC4) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody exhibits potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Lemzoparlimab functions by engaging with the CD47 protein, a key regulator in the 'don't eat me' signal that protects cancer cells from macrophage-mediated phagocytosis. By blocking this signal, Lemzoparlimab promotes the phagocytosis of malignant cells, thereby facilitating an immune response against the tumor. This mechanism highlights its potential utility in studies focused on tumor immunity and therapeutic antibody development.
Lemzoparlimab (TJ011133; TJC4) is a humanized IgG4 monoclonal antibody targeting CD47. This antibody exhibits potent antitumor activity, making it a valuable tool for research in cancer immunotherapy. Lemzoparlimab functions by engaging with the CD47 protein, a key regulator in the 'don't eat me' signal that protects cancer cells from macrophage-mediated phagocytosis. By blocking this signal, Lemzoparlimab promotes the phagocytosis of malignant cells, thereby facilitating an immune response against the tumor. This mechanism highlights its potential utility in studies focused on tumor immunity and therapeutic antibody development.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
